×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
📊
Dashboards
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🧬
Agents
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Dashboards
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Agents
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
←
Home
/
Wiki
/
Mechanism: Gut Microbiome-Derived Lipids and Alpha-Synuclein Aggregatio
mechanism
1,181 words
KG: Gut Microbiome-Derived Lipids and Alpha-Synuclein Aggregation in Parkinson's Disease
Contents
Gut Microbiome-Derived Lipids and Alpha-Synuclein Aggregation in Parkinson's Disease
⚙
Mechanism Info
Name
Gut Microbiome-Derived Lipids and Alpha-Synuclein Aggregation in Parkinson's Disease
No AI portrait yet
Generate portrait ✦
Knowledge Graph
Agent Input
Related Hypotheses (20)
Purinergic Signaling Polarization Control
Score: 0.71
Mechanosensitive Ion Channel Reprogramming
Score: 0.70
Lipid Droplet Dynamics as Phenotype Switches
Score: 0.67
Smartphone-Detected Motor Variability Correction
Score: 0.74
Microbial Metabolite-Mediated α-Synuclein Disaggregation
Score: 0.51
Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cro
Score: 0.64
Restoring Neuroprotective Tryptophan Metabolism via Targeted
Score: 0.61
Enteric Nervous System Prion-Like Propagation Blockade
Score: 0.48
Senescence-Associated Myelin Lipid Remodeling
Score: 0.73
Senescence-Induced Lipid Peroxidation Spreading
Score: 0.73
Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.72
Metabolic Circuit Breaker via Lipid Droplet Modulation
Score: 0.71
Membrane Cholesterol Gradient Modulators
Score: 0.71
Ephrin-B2/EphB4 Axis Manipulation
Score: 0.64
SIRT6-NAD+ Axis Enhancement Therapy
Score: 0.61
Fractalkine Axis Amplification via CX3CR1 Positive Allosteri
Score: 0.56
Gut Barrier Permeability-α-Synuclein Axis Modulation
Score: 0.53
Microbiome-Derived Tryptophan Metabolite Neuroprotection
Score: 0.43
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.74
APOE-Mediated Synaptic Lipid Raft Stabilization
Score: 0.65
Related Analyses (30)
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
Mitochondrial transfer between neurons and glia
neurodegeneration · completed
Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · completed
Mechanistic role of APOE in neurodegeneration
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · archived
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · completed
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · completed
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
Show 25 more
Related Experiments (30)
Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag
clinical · proposed · Score: 0.40
Neural Oscillation Dysfunction Validation in Parkinson's Dis
clinical · proposed · Score: 0.40
Regulated Necrosis Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.40
Experiment Validation: In vitro ThT Assay
validation · proposed · Score: 0.40
Proteasome-Ubiquitin System Dysfunction Validation in Parkin
clinical · proposed · Score: 0.40
Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Purinergic Signaling Dysfunction Validation in Parkinson's D
clinical · proposed · Score: 0.40
Down Syndrome Alzheimer's Disease: Mechanisms and Therapeuti
clinical · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Stress Granule Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Protein Aggregation Kinetic Validation Results
validation · proposed · Score: 0.40
TREM2 Agonist Therapy for Parkinson's Disease — Experimental
validation · proposed · Score: 0.45
Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson'
clinical · proposed · Score: 0.40
Antiviral Therapy Trial for Parkinson's Disease
clinical · proposed · Score: 0.40
Alpha-Synuclein SAA Kinetics Study — Biological Staging Back
clinical · proposed · Score: 0.40
Epigenetic Dysregulation Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation
exploratory · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD
validation · proposed · Score: 0.40
Mechanism: Selective Vulnerability of Dopaminergic Neurons i
validation · proposed · Score: 0.40
DNA Damage Repair Deficiency Validation Study in Parkinson's
clinical · completed · Score: 0.40
Alpha-Synuclein Seed Amplification Assay Validation
clinical · proposed · Score: 0.40
Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa
validation · proposed · Score: 0.40
CRISPR Gene Correction Approaches for CBS/PSP
clinical · proposed · Score: 0.40
Exercise-BDNF-Mitophagy Biomarker Study in PD
clinical · proposed · Score: 0.40
Ferroptosis Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
GLP-1 Agonist Neuroprotection Mechanism in PD
clinical · proposed · Score: 0.40
Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation
validation · proposed · Score: 0.40
Show 25 more
See Also (15)
Alpha-Synuclein PET Imaging and Biomarker Advances
biomarker · Pages share 3 hypotheses
Alpha-Synuclein Seeding Assays (RT-QuIC and PMCA)
biomarker · Pages share 3 hypotheses
Imaging Biomarkers for Corticobasal Syndrome and Progre
biomarker · Pages share 3 hypotheses
Cell-Free DNA Biomarkers in Neurodegeneration
biomarker · Pages share 3 hypotheses
Exosomal Biomarkers in Neurodegeneration
biomarker · Pages share 3 hypotheses
Exosomal miR-155 in Neurodegeneration
biomarker · Pages share 3 hypotheses
IL-6 (Interleukin-6) in Neurodegeneration
biomarker · Pages share 3 hypotheses
Liquid Biopsy in Neurodegeneration
biomarker · Pages share 3 hypotheses
Metabolomic Biomarkers in Neurodegeneration
biomarker · Pages share 3 hypotheses
Multi-Analyte Biomarker Panel for Parkinson's Disease D
biomarker · Pages share 3 hypotheses
Neuroimaging Biomarkers for Neurodegeneration
biomarker · Pages share 3 hypotheses
NPTX1 and NPTXR CSF Markers Predict Alzheimer's Disease
biomarker · Pages share 3 hypotheses
Polygenic Risk Score Integration Panel for Alzheimer's
biomarker · Pages share 3 hypotheses
CSF and Blood Biomarkers in Progressive Supranuclear Pa
biomarker · Pages share 3 hypotheses
AAIC 2026: Tau-PET Imaging and Fluid Biomarker Integrat
biomarker · Pages share 3 hypotheses
Show 10 more
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)